Evidence reviewed: 22 July 2026 · Author: ExtolX Editorial Team · Scientific review: Pending
Educational information for laboratory research audiences. This article does not provide medical advice, dosage or administration guidance.
TB-500 is a name used for a synthetic peptide associated with thymosin beta-4 research. The two terms should not be treated as interchangeable without confirming the precise sequence and material.
Key points
- The compound is a research peptide marketed as a fragment related to thymosin beta-4, an endogenous 43-amino-acid actin-binding protein.
- Evidence from cells, animals and humans must be interpreted separately.
- No MHRA-authorised TB-500 medicine was identified. Thymosin beta-4 and its derivatives are subject to anti-doping restrictions.
- Research findings do not establish that independently supplied material is equivalent to a clinical-trial product.
What is it?
TB-500 is a name used for a synthetic peptide associated with thymosin beta-4 research. The two terms should not be treated as interchangeable without confirming the precise sequence and material. In scientific work, identity should be established through appropriate analytical documentation rather than inferred from a product name alone.
How is it thought to work?
Thymosin beta-4 participates in actin sequestration, cell migration and tissue organisation. Findings concerning the full native protein cannot automatically be assigned to a shorter synthetic fragment.
What does the current evidence show?
- Thymosin beta-4 has been studied in cell migration, angiogenesis, corneal and cardiac models.
- Some human trials concern recombinant or pharmaceutical thymosin beta-4 preparations, not material described commercially as TB-500.
- Direct, sequence-specific evidence for retail TB-500 is substantially thinner than the broader thymosin beta-4 literature.
Evidence snapshot
| Evidence level | What it can establish | Main caution |
|---|---|---|
| Laboratory | Biochemical activity and cellular responses under defined conditions | Does not establish effects in an intact organism |
| Animal | Mechanisms and model-specific biological responses | Translation to humans is uncertain |
| Human | Outcomes in the studied population and formulation | Must not be generalised beyond the actual trial |
What remains unknown?
- Naming and sequence ambiguity makes literature translation unusually difficult.
- Evidence for the full protein is not evidence for every fragment or formulation.
- Clinical safety and efficacy of independently supplied TB-500 have not been established.
Regulatory and safety context
No MHRA-authorised TB-500 medicine was identified. Thymosin beta-4 and its derivatives are subject to anti-doping restrictions. A research-use label does not override the way a product is presented, promoted or used. Safety information from one formulation or jurisdiction cannot be transferred automatically to another.
Frequently asked questions
Does published research prove a benefit?
No. A finding must be interpreted in the context of its model, study design, population, formulation and endpoints. Preliminary or preclinical findings are not proof of clinical benefit.
Is research material equivalent to material used in a clinical trial?
Not on the basis of a shared name. Equivalence would require evidence concerning identity, manufacture, purity, formulation, stability and biological activity.
References and further reading
Research-use notice: ExtolX products are supplied strictly for legitimate laboratory research. They are not intended for human or veterinary use, consumption, diagnosis, treatment or prevention of disease.